Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046

NEXT STORY
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
PREV STORY
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting

author_avatar
NASDAQ Market News

AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

author_avatar
NASDAQ Market News

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update

XERMELO® (telotristat ethyl) U.S. Net Sales Since March 2017 Launch Reach $15.1 Million Regulatory ...

author_avatar
NASDAQ Market News